Clinical Trials Browser

Phase 2 × Withdrawn × Biliary Tract Neoplasms × Clear all

NCT06084689 2025-09-02

EMPIRE

Phase 2 Withdrawn

BreastGastrointestinalSarcomaThoracic

Tertiary Lymphoid Structures, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04571710 2025-07-24

A Trial of SHR1258 in Patients With Biliary Tract Cancer

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms

NCT06017297 2024-11-12

ESR-22-21719

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms

NCT03999658 2023-05-01

A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies

Phase 2 Withdrawn

GastrointestinalLymphoid

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Cholangiocarcinoma, Lymphoma, Extranodal NK-T-Cell

NCT05041972 2022-09-13

ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)

Phase 2 Withdrawn

BreastGastrointestinalThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03110510 2022-06-15

FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms

NCT04796454 2022-06-01

PAMICC

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms

NCT04186156 2021-02-03

A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms

NCT03768531 2020-04-13

Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms

NCT03818997 2020-02-05

DYNAMIC

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms, Esophageal Neoplasms

NCT03129074 2018-05-23

Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms

NCT02720601 2018-01-25

Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms

NCT00487851 2013-04-12

Comparing Endoscopic Based Stent Strategy Versus Bypass Surgery in Non-resectable Periampullary Cancer

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms, Bites and Stings, Duodenal Neoplasms, Jaundice, Neoplasms, Pancreatic Neoplasms